Drug Profile


Alternative Names: CXA-101/tazobactam; CXA-201; MK-7625A; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Cubist Pharmaceuticals; Merck Sharp & Dohme
  • Class 2 ring heterocyclic compounds; Antibacterials; Cephalosporins; Small molecules; Sulfones; Triazoles
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Intra-abdominal infections; Urinary tract infections
  • Registered Pyelonephritis
  • Phase III Nosocomial pneumonia

Most Recent Events

  • 05 Sep 2017 Merck Sharp & Dohme completes a phase III trial in Urinary tract infections in Japan (IV) (NCT02728089)
  • 28 Jul 2017 Merck plans a phase II trial for Urinary tract infection (In neonates, In infants, In children, In adolescents) (NCT03230838)
  • 28 Jul 2017 Merck Sharp & Dohme completes a phase III trial for Intra-abdominal infections (Combination therapy) in Japan (IV) (NCT02739997)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top